A research team led by Professor Wang Jun at South China University of Technology (SCUT) haspublished a paper titled 'Engineering Multi-Specific Nano-Antibodies for Cancer Immunotherapy'in Nature Biomedical Engineering, reporting important research progress in the field of cancerimmunotherapy. By developing multi-specific nano-antibodies and promoting their clinical translationand application, the team has provided new technological pathways and innovative concepts for thefield.

Figure 1: Schematic illustrating the design of FP-NA and multi-NanoAb with the potential to improvemAb-based cancer immunotherapy.

The team updated the "nano-adaptor" technology in the research. Using genetic engineeringtechniques, they constructed a recombinant fusion protein composed of an Fc receptor and serumalbumin. This fusion protein was then controllably assembled with the biomedical polymer polylacticacid in a "one-step" method, resulting in the successful fabrication of a Fusion Protein–polymerComposite "Nano-Adaptor" (FP-NA). This multi-specific nano-antibody significantly enhances theability of immune cells, such as T cells and macrophages, to recognize and eliminate tumor cells. Theteam has completed the scaled-up trial production and key technology validation of the "nanoadaptor," which is expected to overcome the limitations of conventional production technologies,advance the development of new antibody drugs, and open new avenues for treating cancers andother diseases.